Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 361 to 369 of 369 entries
Sorted by: Best Match Show Resources per page
Outcome of Allogeneic Transplantation for Mature T-cell Lymphomas: Impact of Donor Source and Disease Characteristics.

Blood advances

Hamadani M, Ngoya M, Sureda A, Bashir Q, Litovich CA, Finel H, Chen Y, Boumendil A, Zain J, Castagna L, Cashen AF, Blaise D, Shadman M, Pastano R, Khimani F, Arat M, Dietrich S, Schmitz N, Glass B, Kharfan-Dabaja MA, Corradini P, Sauter CS, Montoto S, Kwon M, Herrera AF, Dreger P.
PMID: 34861680
Blood Adv. 2021 Dec 03; doi: 10.1182/bloodadvances.2021005899. Epub 2021 Dec 03.

Mature T-cell lymphomas constitute the most common indication of allogeneic hematopoietic cell transplantation (allo-HCT) in lymphomas. Large studies evaluating contemporary outcomes of allo-HCT in mature T-cell lymphomas, relative to commonly used donor sources are not available. Included in this...

Cite
Hamadani M, Ngoya M, Sureda A, et al. Outcome of Allogeneic Transplantation for Mature T-cell Lymphomas: Impact of Donor Source and Disease Characteristics. Blood Adv. 2021;doi: 10.1182/bloodadvances.2021005899.
Hamadani, M., Ngoya, M., Sureda, A., Bashir, Q., Litovich, C. A., Finel, H., Chen, Y., Boumendil, A., Zain, J., Castagna, L., Cashen, A. F., Blaise, D., Shadman, M., Pastano, R., Khimani, F., Arat, M., Dietrich, S., Schmitz, N., Glass, B., Kharfan-Dabaja, M. A., Corradini, P., Sauter, C. S., Montoto, S., Kwon, M., Herrera, A. F., & Dreger, P. (2021). Outcome of Allogeneic Transplantation for Mature T-cell Lymphomas: Impact of Donor Source and Disease Characteristics. Blood advances, . https://doi.org/10.1182/bloodadvances.2021005899
Hamadani, Mehdi, et al. "Outcome of Allogeneic Transplantation for Mature T-cell Lymphomas: Impact of Donor Source and Disease Characteristics." Blood advances vol. (2021). doi: https://doi.org/10.1182/bloodadvances.2021005899
Hamadani M, Ngoya M, Sureda A, Bashir Q, Litovich CA, Finel H, Chen Y, Boumendil A, Zain J, Castagna L, Cashen AF, Blaise D, Shadman M, Pastano R, Khimani F, Arat M, Dietrich S, Schmitz N, Glass B, Kharfan-Dabaja MA, Corradini P, Sauter CS, Montoto S, Kwon M, Herrera AF, Dreger P. Outcome of Allogeneic Transplantation for Mature T-cell Lymphomas: Impact of Donor Source and Disease Characteristics. Blood Adv. 2021 Dec 03; doi: 10.1182/bloodadvances.2021005899. Epub 2021 Dec 03. PMID: 34861680.
Copy Download .nbib Format: NLM
Correction to: Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV.

BMC infectious diseases

Merlini E, Cozzi-Lepri A, Castagna A, Costantini A, Caputo SL, Carrara S, Quiros-Roldan E, Ursitti MA, Antinori A, D'Arminio Monforte A, Marchetti G.
PMID: 34167481
BMC Infect Dis. 2021 Jun 24;21(1):603. doi: 10.1186/s12879-021-06330-1.

No abstract available.

Cite
Merlini E, Cozzi-Lepri A, Castagna A, et al. Correction to: Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV. BMC Infect Dis. 2021;21(1):603doi: 10.1186/s12879-021-06330-1.
Merlini, E., Cozzi-Lepri, A., Castagna, A., Costantini, A., Caputo, S. L., Carrara, S., Quiros-Roldan, E., Ursitti, M. A., Antinori, A., D'Arminio Monforte, A., & Marchetti, G. (2021). Correction to: Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV. BMC infectious diseases, 21(1), 603. https://doi.org/10.1186/s12879-021-06330-1
Merlini, Esther, et al. "Correction to: Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV." BMC infectious diseases vol. 21,1 (2021): 603. doi: https://doi.org/10.1186/s12879-021-06330-1
Merlini E, Cozzi-Lepri A, Castagna A, Costantini A, Caputo SL, Carrara S, Quiros-Roldan E, Ursitti MA, Antinori A, D'Arminio Monforte A, Marchetti G. Correction to: Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV. BMC Infect Dis. 2021 Jun 24;21(1):603. doi: 10.1186/s12879-021-06330-1. PMID: 34167481; PMCID: PMC8229625.
Copy Download .nbib Format: NLM
Prevalence and risk factors of moderate to severe hepatic steatosis in patients with rheumatoid arthritis: an ultrasonography cross-sectional case-control study.

Therapeutic advances in musculoskeletal disease

Erre GL, Castagna F, Sauchella A, Meloni P, Mangoni AA, Farina G, Woodman R, Dore MP, Vidili G.
PMID: 34819999
Ther Adv Musculoskelet Dis. 2021 Nov 18;13:1759720X211042739. doi: 10.1177/1759720X211042739. eCollection 2021.

BACKGROUND: The independent association between hepatic steatosis and rheumatoid arthritis is poorly defined.METHODS: The presence of moderate to severe steatosis was assessed, using liver ultrasonography, in 364 consecutive non-diabetic subjects (223 patients with rheumatoid arthritis and 141 age- and...

Cite
Erre GL, Castagna F, Sauchella A, et al. Prevalence and risk factors of moderate to severe hepatic steatosis in patients with rheumatoid arthritis: an ultrasonography cross-sectional case-control study. Ther Adv Musculoskelet Dis. 2021;13:1759720X211042739doi: 10.1177/1759720X211042739.
Erre, G. L., Castagna, F., Sauchella, A., Meloni, P., Mangoni, A. A., Farina, G., Woodman, R., Dore, M. P., & Vidili, G. (2021). Prevalence and risk factors of moderate to severe hepatic steatosis in patients with rheumatoid arthritis: an ultrasonography cross-sectional case-control study. Therapeutic advances in musculoskeletal disease, 131759720X211042739. https://doi.org/10.1177/1759720X211042739
Erre, Gian Luca, et al. "Prevalence and risk factors of moderate to severe hepatic steatosis in patients with rheumatoid arthritis: an ultrasonography cross-sectional case-control study." Therapeutic advances in musculoskeletal disease vol. 13 (2021): 1759720X211042739. doi: https://doi.org/10.1177/1759720X211042739
Erre GL, Castagna F, Sauchella A, Meloni P, Mangoni AA, Farina G, Woodman R, Dore MP, Vidili G. Prevalence and risk factors of moderate to severe hepatic steatosis in patients with rheumatoid arthritis: an ultrasonography cross-sectional case-control study. Ther Adv Musculoskelet Dis. 2021 Nov 18;13:1759720X211042739. doi: 10.1177/1759720X211042739. eCollection 2021. PMID: 34819999; PMCID: PMC8606981.
Copy Download .nbib Format: NLM
Sub-Sampled Imaging for STEM: Maximising Image Speed, Resolution and Precision Through Reconstruction Parameter Refinement.

Ultramicroscopy

Nicholls D, Wells J, Stevens A, Zheng Y, Castagna J, Browning ND.
PMID: 34915288
Ultramicroscopy. 2021 Dec 07;233:113451. doi: 10.1016/j.ultramic.2021.113451. Epub 2021 Dec 07.

Sub-sampling during image acquisition in scanning transmission electron microscopy (STEM) has been shown to provide a means to increase the overall speed of acquisition while at the same time providing an efficient means to control the dose, dose rate...

Cite
Nicholls D, Wells J, Stevens A, et al. Sub-Sampled Imaging for STEM: Maximising Image Speed, Resolution and Precision Through Reconstruction Parameter Refinement. Ultramicroscopy. 2021;233:113451doi: 10.1016/j.ultramic.2021.113451.
Nicholls, D., Wells, J., Stevens, A., Zheng, Y., Castagna, J., & Browning, N. D. (2021). Sub-Sampled Imaging for STEM: Maximising Image Speed, Resolution and Precision Through Reconstruction Parameter Refinement. Ultramicroscopy, 233113451. https://doi.org/10.1016/j.ultramic.2021.113451
Nicholls, Daniel, et al. "Sub-Sampled Imaging for STEM: Maximising Image Speed, Resolution and Precision Through Reconstruction Parameter Refinement." Ultramicroscopy vol. 233 (2021): 113451. doi: https://doi.org/10.1016/j.ultramic.2021.113451
Nicholls D, Wells J, Stevens A, Zheng Y, Castagna J, Browning ND. Sub-Sampled Imaging for STEM: Maximising Image Speed, Resolution and Precision Through Reconstruction Parameter Refinement. Ultramicroscopy. 2021 Dec 07;233:113451. doi: 10.1016/j.ultramic.2021.113451. Epub 2021 Dec 07. PMID: 34915288.
Copy Download .nbib Format: NLM
Ribavirin Aerosol in the Treatment of SARS-CoV-2: A Case Series.

Infectious diseases and therapy

Messina E, Danise A, Ferrari G, Andolina A, Chiurlo M, Razanakolona M, Barakat M, Israel RJ, Castagna A.
PMID: 34302258
Infect Dis Ther. 2021 Dec;10(4):2791-2804. doi: 10.1007/s40121-021-00493-9. Epub 2021 Jul 23.

Ribavirin is an inosine monophosphate dehydrogenase inhibitor with demonstrated activity against coronaviruses, including SARS-CoV-2. Five hospitalized patients with COVID-19 (confirmed by positive tests for SARS-CoV-2) received treatment with ribavirin for inhalation solution (ribavirin aerosol) as part of a compassionate...

Cite
Messina E, Danise A, Ferrari G, et al. Ribavirin Aerosol in the Treatment of SARS-CoV-2: A Case Series. Infect Dis Ther. 2021;10(4):2791-2804doi: 10.1007/s40121-021-00493-9.
Messina, E., Danise, A., Ferrari, G., Andolina, A., Chiurlo, M., Razanakolona, M., Barakat, M., Israel, R. J., & Castagna, A. (2021). Ribavirin Aerosol in the Treatment of SARS-CoV-2: A Case Series. Infectious diseases and therapy, 10(4), 2791-2804. https://doi.org/10.1007/s40121-021-00493-9
Messina, Emanuela, et al. "Ribavirin Aerosol in the Treatment of SARS-CoV-2: A Case Series." Infectious diseases and therapy vol. 10,4 (2021): 2791-2804. doi: https://doi.org/10.1007/s40121-021-00493-9
Messina E, Danise A, Ferrari G, Andolina A, Chiurlo M, Razanakolona M, Barakat M, Israel RJ, Castagna A. Ribavirin Aerosol in the Treatment of SARS-CoV-2: A Case Series. Infect Dis Ther. 2021 Dec;10(4):2791-2804. doi: 10.1007/s40121-021-00493-9. Epub 2021 Jul 23. PMID: 34302258; PMCID: PMC8302211.
Copy Download .nbib Format: NLM
Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial.

JAMA network open

Menichetti F, Popoli P, Puopolo M, Spila Alegiani S, Tiseo G, Bartoloni A, De Socio GV, Luchi S, Blanc P, Puoti M, Toschi E, Massari M, Palmisano L, Marano G, Chiamenti M, Martinelli L, Franchi S, Pallotto C, Suardi LR, Luciani Pasqua B, Merli M, Fabiani P, Bertolucci L, Borchi B, Modica S, Moneta S, Marchetti G, d'Arminio Monforte A, Stoppini L, Ferracchiato N, Piconi S, Fabbri C, Beccastrini E, Saccardi R, Giacometti A, Esperti S, Pierotti P, Bernini L, Bianco C, Benedetti S, Lanzi A, Bonfanti P, Massari M, Sani S, Saracino A, Castagna A, Trabace L, Lanza M, Focosi D, Mazzoni A, Pistello M, Falcone M.
PMID: 34842924
JAMA Netw Open. 2021 Nov 01;4(11):e2136246. doi: 10.1001/jamanetworkopen.2021.36246.

IMPORTANCE: Convalescent plasma (CP) has been generally unsuccessful in preventing worsening of respiratory failure or death in hospitalized patients with COVID-19 pneumonia.OBJECTIVE: To evaluate the efficacy of CP plus standard therapy (ST) vs ST alone in preventing worsening respiratory...

Cite
Menichetti F, Popoli P, Puopolo M, et al. Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Netw Open. 2021;4(11):e2136246doi: 10.1001/jamanetworkopen.2021.36246.
Menichetti, F., Popoli, P., Puopolo, M., Spila Alegiani, S., Tiseo, G., Bartoloni, A., De Socio, G. V., Luchi, S., Blanc, P., Puoti, M., Toschi, E., Massari, M., Palmisano, L., Marano, G., Chiamenti, M., Martinelli, L., Franchi, S., Pallotto, C., Suardi, L. R., Luciani Pasqua, B., Merli, M., Fabiani, P., Bertolucci, L., Borchi, B., Modica, S., Moneta, S., Marchetti, G., d'Arminio Monforte, A., Stoppini, L., Ferracchiato, N., Piconi, S., Fabbri, C., Beccastrini, E., Saccardi, R., Giacometti, A., Esperti, S., Pierotti, P., Bernini, L., Bianco, C., Benedetti, S., Lanzi, A., Bonfanti, P., Massari, M., Sani, S., Saracino, A., Castagna, A., Trabace, L., Lanza, M., Focosi, D., Mazzoni, A., Pistello, M., Falcone, M. (2021). Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA network open, 4(11), e2136246. https://doi.org/10.1001/jamanetworkopen.2021.36246
Menichetti, Francesco, et al. "Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial." JAMA network open vol. 4,11 (2021): e2136246. doi: https://doi.org/10.1001/jamanetworkopen.2021.36246
Menichetti F, Popoli P, Puopolo M, Spila Alegiani S, Tiseo G, Bartoloni A, De Socio GV, Luchi S, Blanc P, Puoti M, Toschi E, Massari M, Palmisano L, Marano G, Chiamenti M, Martinelli L, Franchi S, Pallotto C, Suardi LR, Luciani Pasqua B, Merli M, Fabiani P, Bertolucci L, Borchi B, Modica S, Moneta S, Marchetti G, d'Arminio Monforte A, Stoppini L, Ferracchiato N, Piconi S, Fabbri C, Beccastrini E, Saccardi R, Giacometti A, Esperti S, Pierotti P, Bernini L, Bianco C, Benedetti S, Lanzi A, Bonfanti P, Massari M, Sani S, Saracino A, Castagna A, Trabace L, Lanza M, Focosi D, Mazzoni A, Pistello M, Falcone M. Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Netw Open. 2021 Nov 01;4(11):e2136246. doi: 10.1001/jamanetworkopen.2021.36246. PMID: 34842924; PMCID: PMC8630572.
Copy Download .nbib Format: NLM
Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4).

Thyroid : official journal of the American Thyroid Association

Forleo R, Grani G, Alfò M, Zilioli V, Giubbini R, Zatelli MC, Gagliardi I, Piovesan A, Ragni A, Morelli S, Puxeddu E, Pagano L, Deandrea M, Ceresini G, Torlontano M, Puligheddu B, Antonelli A, Centanni M, Fugazzola L, Spiazzi G, Monti S, Rossetto R, Monzani F, Tallini G, Crescenzi A, Sparano C, Bruno R, Repaci A, Tumino D, Pezzullo L, Lombardi CP, Ferraro Petrillo U, Filetti S, Durante C, Castagna MG.
PMID: 34541894
Thyroid. 2021 Dec;31(12):1814-1821. doi: 10.1089/thy.2021.0248. Epub 2021 Oct 20.

No abstract available.

Cite
Forleo R, Grani G, Alfò M, et al. Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4). Thyroid. 2021;31(12):1814-1821doi: 10.1089/thy.2021.0248.
Forleo, R., Grani, G., Alfò, M., Zilioli, V., Giubbini, R., Zatelli, M. C., Gagliardi, I., Piovesan, A., Ragni, A., Morelli, S., Puxeddu, E., Pagano, L., Deandrea, M., Ceresini, G., Torlontano, M., Puligheddu, B., Antonelli, A., Centanni, M., Fugazzola, L., Spiazzi, G., Monti, S., Rossetto, R., Monzani, F., Tallini, G., Crescenzi, A., Sparano, C., Bruno, R., Repaci, A., Tumino, D., Pezzullo, L., Lombardi, C. P., Ferraro Petrillo, U., Filetti, S., Durante, C., & Castagna, M. G. (2021). Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4). Thyroid : official journal of the American Thyroid Association, 31(12), 1814-1821. https://doi.org/10.1089/thy.2021.0248
Forleo, Raffaella, et al. "Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4)." Thyroid : official journal of the American Thyroid Association vol. 31,12 (2021): 1814-1821. doi: https://doi.org/10.1089/thy.2021.0248
Forleo R, Grani G, Alfò M, Zilioli V, Giubbini R, Zatelli MC, Gagliardi I, Piovesan A, Ragni A, Morelli S, Puxeddu E, Pagano L, Deandrea M, Ceresini G, Torlontano M, Puligheddu B, Antonelli A, Centanni M, Fugazzola L, Spiazzi G, Monti S, Rossetto R, Monzani F, Tallini G, Crescenzi A, Sparano C, Bruno R, Repaci A, Tumino D, Pezzullo L, Lombardi CP, Ferraro Petrillo U, Filetti S, Durante C, Castagna MG. Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4). Thyroid. 2021 Dec;31(12):1814-1821. doi: 10.1089/thy.2021.0248. Epub 2021 Oct 20. PMID: 34541894.
Copy Download .nbib Format: NLM
High-Intensity Intermittent Exercise Performed on the Sand Induces Higher Internal Load Demands in Soccer Players.

Frontiers in psychology

Cetolin T, Teixeira AS, da Silva JF, Haupenthal A, Nakamura FY, Castagna C, Guglielmo LGA.
PMID: 34393953
Front Psychol. 2021 Jul 30;12:713106. doi: 10.3389/fpsyg.2021.713106. eCollection 2021.

This study aimed to examine the acute physiological effect of shuttle-run-based high-intensity intermittent exercise (HIIE) performed at the same relative speed (i. e., 100% PS

Cite
Cetolin T, Teixeira AS, da Silva JF, et al. High-Intensity Intermittent Exercise Performed on the Sand Induces Higher Internal Load Demands in Soccer Players. Front Psychol. 2021;12:713106doi: 10.3389/fpsyg.2021.713106.
Cetolin, T., Teixeira, A. S., da Silva, J. F., Haupenthal, A., Nakamura, F. Y., Castagna, C., & Guglielmo, L. G. A. (2021). High-Intensity Intermittent Exercise Performed on the Sand Induces Higher Internal Load Demands in Soccer Players. Frontiers in psychology, 12713106. https://doi.org/10.3389/fpsyg.2021.713106
Cetolin, Tiago, et al. "High-Intensity Intermittent Exercise Performed on the Sand Induces Higher Internal Load Demands in Soccer Players." Frontiers in psychology vol. 12 (2021): 713106. doi: https://doi.org/10.3389/fpsyg.2021.713106
Cetolin T, Teixeira AS, da Silva JF, Haupenthal A, Nakamura FY, Castagna C, Guglielmo LGA. High-Intensity Intermittent Exercise Performed on the Sand Induces Higher Internal Load Demands in Soccer Players. Front Psychol. 2021 Jul 30;12:713106. doi: 10.3389/fpsyg.2021.713106. eCollection 2021. PMID: 34393953; PMCID: PMC8360849.
Copy Download .nbib Format: NLM
Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer.

The Prostate

Haffner MC, Bhamidipati A, Tsai HK, Esopi DM, Vaghasia AM, Low JY, Patel RA, Guner G, Pham MT, Castagna N, Hicks J, Wyhs N, Aebersold R, De Marzo AM, Nelson WG, Guo T, Yegnasubramanian S.
PMID: 34402095
Prostate. 2021 Nov;81(15):1159-1171. doi: 10.1002/pros.24210. Epub 2021 Aug 16.

BACKGROUND: Resistance to androgen deprivation therapies is a major driver of mortality in advanced prostate cancer. Therefore, there is a need to develop new preclinical models that allow the investigation of resistance mechanisms and the assessment of drugs for...

Cite
Haffner MC, Bhamidipati A, Tsai HK, et al. Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer. Prostate. 2021;81(15):1159-1171doi: 10.1002/pros.24210.
Haffner, M. C., Bhamidipati, A., Tsai, H. K., Esopi, D. M., Vaghasia, A. M., Low, J. Y., Patel, R. A., Guner, G., Pham, M. T., Castagna, N., Hicks, J., Wyhs, N., Aebersold, R., De Marzo, A. M., Nelson, W. G., Guo, T., & Yegnasubramanian, S. (2021). Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer. The Prostate, 81(15), 1159-1171. https://doi.org/10.1002/pros.24210
Haffner, Michael C, et al. "Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer." The Prostate vol. 81,15 (2021): 1159-1171. doi: https://doi.org/10.1002/pros.24210
Haffner MC, Bhamidipati A, Tsai HK, Esopi DM, Vaghasia AM, Low JY, Patel RA, Guner G, Pham MT, Castagna N, Hicks J, Wyhs N, Aebersold R, De Marzo AM, Nelson WG, Guo T, Yegnasubramanian S. Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer. Prostate. 2021 Nov;81(15):1159-1171. doi: 10.1002/pros.24210. Epub 2021 Aug 16. PMID: 34402095; PMCID: PMC8460612.
Copy Download .nbib Format: NLM
Showing 361 to 369 of 369 entries